Arrowhead Pharmaceuticals, Inc.
ARROWHEAD RESEARCH CORP (Form: 10-Q, Received: 02/09/2015 16:10:22)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2014

¨

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-21898

 

ARROWHEAD RESEARCH CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

46-0408024

(State of incorporation)

 

(I.R.S. Employer Identification No.)

225 S. Lake Avenue, Suite 1050

Pasadena, California 91101

(626) 304-3400

(Address and telephone number of principal executive offices)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated

 

x

  

Accelerated filer

 

¨

 

 

 

 

Non-accelerated filer

 

¨   (Do not check if a smaller reporting company)

  

Smaller reporting company

 

¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x

The number of shares of the registrant’s common stock outstanding as of February 5, 2015 was 54,792,649.

 

 

 

 

 

 


 

Page(s)

PART I — FINANCIAL INFORMATION

 

 

 

ITEM 1. FINANCIAL STATEMENTS (unaudited)

1

 

 

Consolidated Balance Sheets

1

 

 

Consolidated Statements of Operations

2

 

 

Consolidated Statement of Stockholders’ Equity

3

 

 

Consolidated Statements of Cash Flows

4

 

 

Notes to Consolidated Financial Statements

5

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

16

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

23

 

 

ITEM 4. CONTROLS AND PROCEDURES

23

 

 

PART II — OTHER INFORMATION

 

 

 

ITEM 1. LEGAL PROCEEDINGS

24

 

 

ITEM 1A. RISK FACTORS

24

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

24

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

24

 

 

ITEM 4. MINE SAFETY DISCLOSURES

24

 

 

ITEM 5. OTHER INFORMATION

24

 

 

ITEM 6. EXHIBITS

25

 

 

SIGNATURE

26

 

 

 

 


PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

Arrowhead Research Corporation

Consolidated Balance Sheets

 

 

(unaudited)

 

 

 

 

 

 

December 31, 2014

 

 

September 30, 2014

 

ASSETS

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

 

Cash and cash equivalents

$

103,991,231

 

 

$

132,510,610

 

Trade receivables

 

127,000

 

 

 

-

 

Prepaid expenses

 

4,451,124

 

 

 

588,626

 

Other current assets

 

62,841

 

 

 

48,502

 

Short term investments

 

23,532,402

 

 

 

21,653,032

 

TOTAL CURRENT ASSETS

 

132,164,598

 

 

 

154,800,770

 

Property and equipment, net

 

4,124,441

 

 

 

3,872,753

 

Intangible assets, net

 

999,809

 

 

 

1,013,473

 

Investments

 

17,806,499

 

 

 

23,088,346

 

Other assets

 

7,041,414

 

 

 

41,414

 

TOTAL ASSETS

$

162,136,761

 

 

$

182,816,756

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

Accounts payable

$

5,994,951

 

 

$

2,579,478

 

Accrued expenses

 

1,148,092

 

 

 

1,399,486

 

Accrued payroll and benefits

 

2,175,484

 

 

 

3,268,506

 

Deferred revenue

 

109,375

 

 

 

103,125

 

Derivative liabilities

 

1,790,559

 

 

 

4,173,943

 

Capital lease obligation

 

213,991

 

 

 

213,991

 

Notes payable

 

-

 

 

 

50,000

 

Other current liabilities

 

65,213

 

 

 

58,495

 

TOTAL CURRENT LIABILITIES

 

11,497,665

 

 

 

11,847,024

 

LONG-TERM LIABILITIES

 

 

 

 

 

 

 

Capital lease obligation, net of current portion

 

705,173

 

 

 

758,340

 

Contingent consideration obligations

 

3,970,931

 

 

 

3,970,931

 

Other non-current liabilities

 

253,321

 

 

 

255,206

 

TOTAL LONG-TERM LIABILITIES

 

4,929,425

 

 

 

4,984,477

 

Commitments and contingencies

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

Arrowhead Research Corporation stockholders' equity:

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 shares authorized; 18,300 and 18,300 shares

 

 

 

 

 

 

 

issued and outstanding as of December 31, 2014 and September 30, 2014, respectively

 

18

 

 

 

18

 

Common stock, $0.001 par value; 145,000,000 shares authorized; 54,715,714 and 54,656,936 shares

 

 

 

 

 

 

 

issued and outstanding as of December 31, 2014 and September 30, 2014, respectively

 

147,085

 

 

 

147,026

 

Additional paid-in capital

 

393,464,197

 

 

 

391,164,558

 

Accumulated deficit during the development stage

 

(247,346,441

)

 

 

(224,771,159

)

Total Arrowhead Research Corporation stockholders' equity

 

146,264,859

 

 

 

166,540,443

 

Noncontrolling interest

 

(555,188

)

 

 

(555,188

)

TOTAL STOCKHOLDERS’ EQUITY

 

145,709,671

 

 

 

165,985,255

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

162,136,761

 

 

$

182,816,756

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

 

1


Arrowhead Research Corporation

Consolidated Statements of Operations

(unaudited)

 

 

 

Three Months ended

 

 

Three Months ended

 

 

 

December 31, 2014

 

 

December 31, 2013

 

REVENUE

 

$

170,750

 

 

$

43,750

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

Research and development

 

 

17,744,312

 

 

 

3,133,014

 

Salaries and payroll-related costs

 

 

3,150,617

 

 

 

2,081,791

 

General and administrative expenses

 

 

2,086,202

 

 

 

913,784

 

Stock-based compensation

 

 

2,014,856

 

 

 

521,138

 

Depreciation and amortization

 

 

290,039

 

 

 

403,405

 

TOTAL OPERATING EXPENSES

 

 

25,286,026

 

 

 

7,053,132

 

OPERATING LOSS

 

 

(25,115,276

)

 

 

(7,009,382

)

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

Equity in income (loss) of unconsolidated affiliates

 

 

-

 

 

 

(138,456

)

Gain (loss) on sale of fixed assets, net

 

 

(26,381

)

 

 

(53,562

)

Interest income (expense), net

 

 

237,417

 

 

 

40,578

 

Change in value of derivatives

 

 

2,382,142

 

 

 

(3,519,579

)

Other income (expense)

 

 

(53,184

)

 

 

(5,331

)

TOTAL OTHER INCOME (EXPENSE)

 

 

2,539,994

 

 

 

(3,676,350

)

LOSS BEFORE INCOME TAXES

 

 

(22,575,282

)

 

 

(10,685,732

)

Provision for income taxes

 

 

-

 

 

 

-

 

NET LOSS

 

 

(22,575,282

)

 

 

(10,685,732

)

Net loss attributable to noncontrolling interests

 

 

-

 

 

 

57,420

 

NET LOSS ATTRIBUTABLE TO ARROWHEAD

 

$

(22,575,282

)

 

$

(10,628,312

)

NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD

 

 

 

 

 

 

 

 

           SHAREHOLDERS - BASIC & DILUTED:

 

$

(0.41

)

 

$

(0.28

)

Weighted average shares outstanding - basic and diluted

 

 

54,692,392

 

 

 

37,741,743

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

 

2


Arrowhead Research Corporation

Consolidated Statement of Stockholders’ Equity

(unaudited)

 

 

Preferred Stock

 

 

Common Stock

 

 

Additional Paid-

 

 

Accumulated

 

 

Non-controlling

 

 

 

 

 

 

Shares

 

 

Amount ($)

 

 

Shares

 

 

Amount ($)

 

 

in Capital

 

 

Deficit

 

 

interest

 

 

Totals

 

Balance at September 30, 2013

 

9,900

 

 

$

10

 

 

 

32,489,444

 

 

$

124,859

 

 

$

193,514,766

 

 

$

(166,140,969

)

 

$

(1,763,877

)

 

$

25,734,789

 

Exercise of warrants

 

-

 

 

 

-

 

 

 

2,911,919

 

 

 

2,911

 

 

 

10,145,133

 

 

 

-

 

 

 

-

 

 

 

10,148,044

 

Exercise of stock options

 

-

 

 

 

-

 

 

 

454,863

 

 

 

455

 

 

 

2,729,545

 

 

 

-

 

 

 

-

 

 

 

2,730,000

 

Stock-based compensation

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,696,173

 

 

 

-

 

 

 

-

 

 

 

5,696,173

 

Common stock issued @ $5.86

 

-

 

 

 

-

 

 

 

3,071,672

 

 

 

3,072

 

 

 

14,057,040

 

 

 

-

 

 

 

-

 

 

 

14,060,112

 

Common stock issued @ $18.95

 

-

 

 

 

-

 

 

 

6,325,000

 

 

 

6,325

 

 

 

112,575,234

 

 

 

-

 

 

 

-

 

 

 

112,581,559

 

Preferred stock issued @ $1,000 per share

 

46,000

 

 

 

46

 

 

 

-

 

 

 

-

 

 

 

45,999,954

 

 

 

-

 

 

 

-

 

 

 

46,000,000

 

Common stock issued to Galloway

 

-

 

 

 

-

 

 

 

131,579

 

 

 

132

 

 

 

499,868

 

 

 

-

 

 

 

-

 

 

 

500,000

 

Settlements related to derivative liability

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,956,079

 

 

 

-

 

 

 

-

 

 

 

5,956,079

 

Preferred stock converted to common stock

 

(37,600

)

 

 

(38

)

 

 

9,272,459

 

 

 

9,272

 

 

 

(9,234

)

 

 

-

 

 

 

-

 

 

 

-

 

Deconsolidation of Calando Pharmaceuticals, Inc.

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,303,911

 

 

 

1,303,911

 

Net loss for the year ended September 30, 2014

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(58,630,190

)

 

 

(95,222

)

 

 

(58,725,412

)

Balance at September 30, 2014

 

18,300

 

 

$

18

 

 

 

54,656,936

 

 

$

147,026

 

 

$

391,164,558

 

 

$

(224,771,159

)

 

$

(555,188

)

 

$

165,985,255

 

Exercise of warrants

 

-

 

 

 

-

 

 

 

53,578

 

 

 

53

 

 

 

270,571

 

 

 

-

 

 

 

-

 

 

 

270,624

 

Exercise of stock options

 

-

 

 

 

-

 

 

 

2,500

 

 

 

3

 

 

 

12,973

 

 

 

-

 

 

 

-

 

 

 

12,976

 

Stock-based compensation

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,014,856

 

 

 

-

 

 

 

-

 

 

 

2,014,856

 

Exercise of exchange rights

 

-

 

 

 

-

 

 

 

2,700

 

 

 

3

 

 

 

1,239

 

 

 

-

 

 

 

-

 

 

 

1,242

 

Net loss for the three months ended December 31, 2014

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(22,575,282

)

 

 

-

 

 

 

(22,575,282

)

Balance at December 31, 2014

 

18,300

 

 

$

18

 

 

 

54,715,714

 

 

$

147,085

 

 

$

393,464,197

 

 

$

(247,346,441

)

 

$

(555,188

)

 

$

145,709,671

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

 

3


Arrowhead Research Corporation

Consolidated Statements of Cash Flows

(unaudited)

 

 

 

Three months ended

 

 

Three months ended

 

 

 

 

December 31, 2014

 

 

December 31, 2013

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

Net loss

 

$

(22,575,282

)

 

$

(10,685,732

)

 

Net loss attributable to non-controlling interests

 

 

-

 

 

 

57,420

 

 

Net loss attributable to Arrowhead

 

 

(22,575,282

)

 

 

(10,628,312

)

 

(Gain) loss on disposal of fixed assets

 

 

26,381

 

 

 

53,562

 

 

Change in value of derivatives

 

 

(2,382,142

)

 

 

3,519,579

 

 

Stock-based compensation

 

 

2,014,856

 

 

 

521,138

 

 

Depreciation and amortization

 

 

290,039

 

 

 

403,405

 

 

Amortization/accretion of note premiums/discounts, net

 

 

347,703

 

 

 

28,443

 

 

Non-controlling interest

 

 

-

 

 

 

(57,420

)

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Receivables

 

 

(127,000

)

 

 

(11,825

)

 

Other receivables

 

 

(9,506

)

 

 

-

 

 

Prepaid expenses

 

 

(3,874,051

)

 

 

(74,455

)

 

Accounts payable

 

 

3,415,473

 

 

 

(610,284

)

 

Accrued expenses

 

 

(1,325,675

)

 

 

56,648

 

 

Other liabilities

 

 

(802

)

 

 

(222,811

)

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(24,200,006

)

 

 

(7,022,332

)

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(554,945

)

 

 

(116,215

)

 

Proceeds from sale of fixed assets

 

 

500

 

 

 

-

 

 

Purchase of marketable securities

 

 

-

 

 

 

(19,075,306

)

 

Proceeds from sale of marketable securities

 

 

3,054,774

 

 

 

4,045,956

 

 

Other investing activities

 

 

(7,000,000

)

 

 

-

 

 

NET CASH USED IN INVESTING ACTIVITIES

 

 

(4,499,671

)

 

 

(15,145,565

)

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

Principal payments on capital leases and notes payable

 

 

(103,168

)

 

 

(54,715

)

 

Proceeds from issuance of common stock and preferred stock, net

 

 

-

 

 

 

62,821,592

 

 

Proceeds from the exercise of warrants and stock options

 

 

283,466

 

 

 

-

 

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

 

 

180,298

 

 

 

62,766,877

 

 

NET INCREASE (DECREASE) IN CASH

 

 

(28,519,379

)

 

 

40,598,980

 

 

CASH AT BEGINNING OF PERIOD

 

 

132,510,610

 

 

 

19,114,444

 

 

CASH AT END OF PERIOD

 

$

103,991,231

 

 

$

59,713,424

 

 

Supplementary disclosures:

 

 

 

 

 

 

 

 

 

Interest paid

 

$

3,938

 

 

$

9,496

 

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 

 

4


Arrowhead Research Corporation

Notes to Consolidated Financial Statements

(unaudited)

Unless otherwise noted, (1) the term “Arrowhead” refers to Arrowhead Research Corporation, a Delaware corporation, (2) the terms the “Company,” “we,” “us,” and “our,” refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term “Subsidiaries” refers collectively to Arrowhead Madison Inc. (“Madison”) and Ablaris Therapeutics, Inc. (“Ablaris”), (4) the term “Common Stock” refers to Arrowhead’s Common Stock, (5) the term “Preferred Stock” refers to Arrowhead’s Preferred Stock and the term “Stockholder(s)” refers to the holders of Arrowhead Common Stock.

 

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Arrowhead Research Corporation develops novel drugs to treat intractable diseases by silencing the genes that cause them.  Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products.  The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Liquidity

Historically, the Company’s primary source of financing has been through the sale of securities of Arrowhead. Research and development activities have required significant capital investment since the Company’s inception. We expect our operations to continue to require cash investment in fiscal 2015 and beyond as the Company pursues its research and development goals, as well as clinical trials and related drug manufacturing.  

At December 31, 201 4 , the Company had $104.0 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 24 months.  These bonds provide a source of liquidity, though the Company plans to hold them until maturity.  At December 31, 2014, the Company had invested $41.3 million in bonds.  During the three months ended December 31, 2014, the Company’s cash position decreased by $ 28.5 million which was primarily the result of cash outflows related to continuing operating activities of $24.2 million, other investing activities of $7.0 million and capital expenditures of $0.5 million.  These outflows were partially offset by maturities of fixed income investments totaling $3.1 million and proceeds from the exercise of warrants and options of $0.3 million.

Summary of Significant Accounting Policies

Principles of Consolidation—The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.  Arrowhead’s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company’s research and development facility is located.  All significant intercompany accounts and transactions are eliminated in consolidation.

Basis of Presentation and Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation.

Cash and Cash Equivalents—The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.  The Company had no restricted cash at December 31, 2014 and September 30, 2014.

Concentration of Credit Risk—The Company maintains several bank accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.

5


Investments—The Company may invest excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments – Debt and Equity Securities. This statement requires certain securities to be classified into three categories:

Held-to-maturity—Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost.

Trading Securities—Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings.

Available-for-Sale—Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity.

The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At December 31 , 2014, the Company classified all of its investments as held-to-maturity.

Held-to-maturity investments are measured and recorded at amortized cost on the Company’s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.

Property and Equipment—Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.

Intangible Assets Subject to Amortization—At December 31 , 201 4 , intangible assets subject to amortization include certain license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable.

In-Process Research & Development (IPR&D)—IPR&D assets represent capitalized on-going research projects that were acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step.

Contingent Consideration - The consideration for the Company’s acquisitions often includes future payments that are contingent upon the occurrence of a particular event.  For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.  Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within the Company’s Consolidated Statements of Operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.

6


Revenue Recognition—Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments.

Payments under collaborative research and development agreements are recognized as revenue ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.

Allowance for Doubtful Accounts—The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.

Research and Development—Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company’s research and development operations, and costs to acquire technology licenses.

Earnings (Loss) per Share—Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees and warrants to purchase Common Stock of the Company.  All outstanding stock options, restricted stock units and warrants for the three months ended December 31, 2014 and 2013 have been excluded from the calculation of Diluted earnings (loss) per share due to their anti-dilutive effect.     

Stock-Based Compensation—The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate.

Derivative Assets and Liabilities – The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company’s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company’s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company’s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate.

Income Taxes—The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.

 

7


NOTE 2. PROPERTY AND EQUIPMENT

The following table summarizes our major classes of property and equipment:

 

 

 

 

 

December 31, 2014

 

 

September 30, 2014

 

Computers, office equipment and furniture

$

374,535

 

 

$

334,162

 

Research equipment

 

5,010,151

 

 

 

4,614,176

 

Software

 

69,623

 

 

 

69,623

 

Leasehold improvements

 

3,117,537

 

 

 

3,045,022

 

Total gross fixed assets

 

8,571,846

 

 

 

8,062,983

 

Less:   Accumulated depreciation and amortization

 

(4,447,405

)

 

 

(4,190,230

)

Property and equipment, net

$

4,124,441

 

 

$

3,872,753

 

 

NOTE 3. INVESTMENTS

The Company invests its excess cash balances in short-term and long-term debt securities.  Investments at December 31, 2014 consisted of corporate bonds with maturities remaining of less than two years at the time of purchase.  The Company may also invest excess cash balances in certificates of deposit, money market accounts, US Treasuries, US government agency obligations, corporate debt securities, and/or commercial paper.  The Company accounts for its investments in accordance with FASB ASC 320, Investments – Debt and Equity Securities.  At December 31 , 2014, all investments were classified as held-to-maturity securities.

The following tables summarize the Company’s short and long-term investments as of December 31, 2014, and September 30, 2014.

 

 

As of December 31, 2014

 

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Value

 

Commercial notes (due within one year)

$

23,532,402

 

 

$

 

 

$

(313,407

)

 

$

23,218,995

 

Commercial notes (due after one year through two years)

$

17,806,499

 

 

 

 

 

$

(266,426

)

 

$

17,540,073

 

Total

$

41,338,901

 

 

$

 

 

$

(579,833

)

 

$

40,759,068

 

 

 

As of September 30, 2014

 

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Value

 

Commercial notes (due within one year)

$

21,653,032

 

 

$

 

 

$

(189,830

)

 

$

21,463,202

 

Commercial notes (due after one year through two years)

$

23,088,346

 

 

 

 

 

$

(217,693

)

 

$

22,870,653

 

Total

$

44,741,378

 

 

$

 

 

$

(407,523

)

 

$

44,333,855

 

 

NOTE 4. INTANGIBLE ASSETS

Intangible assets consist of in-process research and development (“IPR&D”) not subject to amortization, and license agreements subject to amortization, which were capitalized as a part of a business combination.

IPR&D represents projects that have not yet received regulatory approval and are required to be classified as indefinite assets until the successful completion or the abandonment of the associated R&D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&D project. At that time, the Company will determine the useful life of the asset, reclassify the asset out of IPR&D and begin amortization. If the associated R&D effort is abandoned the related IPR&D assets will likely be written off and the Company would record an impairment loss.

Intangible assets not subject to amortization include IPR&D capitalized as part of a business combination from the acquisition of Roche Madison.

8


Intangible assets subject to amortization include license agreements capitalized as part of a business combination from the acquisition of Roche Madison. The license agreements are being amortized over the estimated life remaining at the time of acquisition, which was 4 years, and the accumulated amortization of the assets is approximately $175,100. Amortization expense for the three months ended December 31, 2014 and 2013 was $13,700 and $13,700, respectively.  Amortization expense is expected to be approximately $41,900 for the remainder of fiscal year 201 5 , $13,000 in 2016, and zero thereafter.

The following table provides details on the Company’s intangible asset balances:

 

 

Intangible assets
not subject to
amortization

 

  

Intangible assets
subject to
amortization

 

 

Total
Intangible assets

 

Balance at September 30, 2013

$

3,117,322

 

 

$

123,191

 

 

$

3,240,513

 

Impairment

 

(2,172,387

)

 

 

-

 

 

 

(2,172,387

)

Amortization

 

-

 

 

 

(54,653

)

 

 

(54,653

)

Balance at September 30, 2014

$

944,935

 

 

$

68,538

 

 

$

1,013,473

 

Amortization

 

-

 

 

 

(13,664

)

 

 

(13,664

)

Balance at December 31, 2014

$

944,935

 

 

$

54,874

 

 

$

999,809

 

 

NOTE 5. STOCKHOLDERS’ EQUITY

At December 31, 201 4 , the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share.

At December 31, 201 4 , 54,715,714 shares of Common Stock were outstanding.  Additionally, 18,300 shares of Preferred Stock were outstanding, including 2,300 shares of Series B Preferred Stock, convertible into 1,256,831 shares of Common Stock, and 16,000 shares of Series C Preferred Stock, convertible into 2,730,375 shares of Common Stock. At December 31, 2014, 7,274,674 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead’s 2004 Equity Incentive Plan and 2013 Incentive Plan, as well as for inducement grants made to new employees.

The Preferred Stock is convertible to Common Stock by its holder at its stated conversion price, though it is not convertible to the extent the holder would beneficially own more than 9.99% of the number of shares of outstanding Common Stock immediately after the conversion.  The holders of Preferred Stock are eligible to vote with the Common Stock of the Company on an as-converted basis, but only to the extent they are eligible for conversion without exceeding the 9.99% ownership limitation. The Preferred Stock does not carry a coupon, but it is entitled to receive dividends on a pari passu basis with Common Stock, when and if declared.  In any liquidation or dissolution of the Company, the holders of Preferred Stock are entitled to participate in the distribution of the assets, to the extent legally available for distribution, on a pari passu basis with the Common Stock.

On October 11, 2013, the Company sold 3,071,672 shares of Common Stock, at a price of $5.86 per share, and 46,000 shares of Series C Preferred Stock, at a price of $1,000 per share. The Preferred Shares are convertible into shares of common stock at a conversion price of $5.86. The aggregate purchase price paid by the purchasers for the Common Stock and Series C Preferred Stock was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses.

On February 24, 2014, the Company sold 6,325,000 shares of Common Stock, at a public offering price of $18.95 per share.  Net proceeds were approximately $112.6 million after underwriting commissions and discounts and other offering expenses.

The following table summarizes information about warrants outstanding at December 31, 201 4 :

 

Exercise prices

 

Number of 
Warrants

 

 

Remaining
Life in Years

 

$

70.60

 

 

94,897

 

 

 

2.4

 

$

5.00

 

 

390,625

 

 

 

0.7

 

$

5.09

 

 

239,534

 

 

 

0.5

 

$

1.38

 

 

24,324

 

 

 

1.0

 

$

4.16

 

 

1,000

 

 

 

2.0

 

$

3.25

 

 

334,347

 

 

 

1.6

 

$

2.12

 

 

75,000

 

 

 

3.0

 

$

1.83

 

 

277,284

 

 

 

3.0

 

Total warrants outstanding

 

 

1,437,011

 

 

 

 

 

 

9


NOTE 6. COMMITMENTS AND CONTINGENCIES

Leases

The Company leases office space for its corporate headquarters in Pasadena, California. In March 2014, the Company signed a lease addendum to expand its corporate headquarters, and the new space became available in September 2014.  The leases for the expansion space and the current space will expire in September 2019.   Rental costs, including the expansion space, are approximately $23,000 per month, increasing approximately 3% annually.

The Company’s research facility in Madison, Wisconsin is leased through February 28, 2019. Monthly rental expense is approximately $25,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $16,000 per month. Utilities costs are approximately $15,000 per month. Total monthly costs are approximately $75,000 per month, including monthly payments recorded under a capital lease of approximately $19,000.  

Facility rent expense for the three months ended December 31, 2014 and 201 3 was $171,500 and $ 145,000 , respectively.

As of December 31, 201 4 , future minimum lease payments due in fiscal years under capitalized leases are as follows:

 

2015 (remainder of)

$

171,315

 

201 6

 

228,420

 

201 7

 

228,420

 

201 8

 

228,420

 

201 9

 

95,178

 

2020 and thereafter

 

-

 

Less interest

 

(32,589

)

Principal

 

919,164

 

Less current portion

 

(213,991

)

Noncurrent portion

$

705,173

 

As of December 31, 201 4 , future minimum lease payments due in fiscal years under operating leases are as follows:

 

201 5 (remainder of)

$

436,532

 

201 6

 

596,877

 

201 7

 

613,664

 

201 8

 

637,897

 

201 9

 

459,633

 

2020 and thereafter

 

-

 

Total

$

2,744,603

 

Litigation

The Company, its Chief Executive Officer and its Chief Operating Officer have been named as defendants in two securities class actions filed in the United States District Court for the Central District of California regarding certain public statements in connection with the Company’s hepatitis B drug research.  Both actions assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and seek damages in an unspecified amount.  Additionally, three putative stockholder derivative action have been filed in the United States District Court for the Central District of California, alleging breach of fiduciary duty by the Company’s Board of Directors in connection with the facts underlying the Securities Claims.  Each of these five suits seek damages in unspecified amounts and some seek various forms of injunctive relief.   

The Company and two of its former executives have been named as defendants in a complaint filed by William Marsh Rice University (“Rice University”) currently pending in the United States District Court for the Southern District of Texas relating to alleged breaches of a license agreement between Rice University and the Company’s former subsidiary, Unidym, Inc. The plaintiff has alleged that the Company and its former executives acted fraudulently with respect to Unidym’s license from Rice University and seeks injunctive relief, damages, including unspecified compensatory and punitive damages, and attorneys’ fees. 

The Company believes it has a meritorious defense and intends to vigorously defend itself in each of the above matters.  The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount can be reasonably estimated.  No such liability has been recorded related to these matters.  The Company does not expect these matters to have any material effect on its Consolidated Financial Statements. With regard to legal fees, such as attorney fees related to these matters or any other legal matters, the Company’s accounting policy is to recognize such cost as incurred.

10


Purchase Commitments

In the normal course of business, we enter into various purchase commitments for the manufacture of drug components, toxicology studies, and for clinical studies.  As of December 31, 2014, these future commitments were approximately $43.1 million, of which approximately $31.6 million is expected to be incurred in the remainder of fiscal 2015, and $11.5 million is expected to be incurred beyond fiscal 2015. 

Technology License Commitments

The Company has licensed from third parties the rights to use certain technologies that it uses in its research and development activities, as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments.  Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones.  These milestone payments could amount to the mid to upper double digit millions of dollars.  In certain agreements, the Company may be required to make mid to high single digit percentage royalty payments based on a percentage of the sales of the relevant products.

 

NOTE 7. STOCK-BASED COMPENSATION

Arrowhead has two plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, 2,657,352 and 4,000,000 shares, respectively, of Arrowhead’s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards by the Board of Directors to employees, consultants and others. As of December 31, 2014, there were options granted and outstanding to purchase 2,561,018 and 1,686,000 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 470,000 restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of December 31, 2014, there were 617,322 shares reserved for options and restricted stock units issued as inducement grants to new employees outside of equity compensation plans. During the three months ended December 31, 2014, no options were granted under the 2004 Equity Incentive Plan, 864,000 options were granted under the 2013 Incentive Plan, and 120,000 options and 30,000 restricted stock units were granted as inducement awards to new employees outside of equity incentive plans.  Additionally, the Company’s 2000 Stock Option Plan and the 38,000 stock options that were outstanding under the 2000 Stock Option Plan expired during the three months ended December 31, 2014.

The following tables summarize information about stock options:

 

 

Number of
Options
Outstanding

 

 

Weighted-
Average
Exercise
Price
Per Share

 

  

Weighted-
Average
Remaining
Contractual
Term

 

  

Aggregate
Intrinsic
Value

 

Balance At September 30, 201 3

 

3,419,285

  

 

$

4.68

  

  

 

 

 

 

 

 

 

Granted

 

1,039,000

 

 

 

14.05

  

  

 

 

 

 

 

 

 

Cancelled

 

(152,582)

 

 

 

6.05

  

  

 

 

 

 

 

 

 

Exercised

 

(454,863)

 

 

 

6.00

  

  

 

 

 

 

 

 

 

Balance At September 30, 201 4

 

3,850,840

 

 

 

6.99

  

  

 

 

 

 

 

 

 

Granted

 

984,000

 

 

 

5.45

  

  

 

 

 

 

 

 

 

Cancelled

 

(38,000)

 

 

 

18.46

  

  

 

 

 

 

 

 

 

Exercised

 

(2,500)

 

 

 

5.19

  

  

 

 

 

 

 

 

 

Balance At December 31, 2014

 

4,794,340

  

 

$

6.59

  

  

 

8.4 years

 

 

$

11,479,110

 

Exercisable At December 31, 2014

 

1,860,703

 

 

$

5.80

 

 

 

7.3 years

 

 

$

5,106,714

 

Stock-based compensation expense related to stock options for the three months ended December 31, 2014 and 201 3 was $981,399 and $ 521,138 , respectively. The Company does not recognize an income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.

The fair value of the options granted by Arrowhead for the three months ended December 31, 2014 and 2013 is estimated at $ 3,596,618 and $ 531,510 , respectively.

The intrinsic value of the options exercised during the three months ended December 31, 201 4 and 201 3 was $23,774 and $ 314,858 , respectively.

11


As of December 31, 201 4 , the pre-tax compensation expense for all outstanding unvested stock options in the amount of approximately $13,093,446 will be recognized in our results of operations over a weighted average period of 3.1 years.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by our stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

The assumptions used to value stock options are as follows:

 

 

 

Three months ended December 31,

 

 

201 4

 

201 3

Dividend yield

 

 

Risk-free interest rate

 

1.61 – 1.85%

 

1.90%

Volatility

 

75%

 

69%

Expected life (in years)

 

6.25

 

6.25

Weighted average grant date fair value per share of options granted

 

$3.66

 

$5.06

The dividend yield is zero as the Company currently does not pay a dividend.

The risk-free interest rate is based on the U.S. Treasury bond.

Volatility is estimated based on volatility average of the Company’s Common Stock price.

Restricted Stock Units

Restricted Stock Units (RSUs) were granted under the Company’s 2013 Incentive Plan and inducement grants granted outside of the Plan.  During the three months ended December 31, 2014 and 2013, the Company issued 30,000 and 0 restricted stock units, respectively, to certain members of management.  Of the restricted stock units granted during the three months ended December 31, 2014, 30,000 were granted outside of the Plan as an inducement grant to a new employee. At vesting each RSU will be exchanged for one share of the Company’s Common Stock. The RSUs issued during the three months ended December 31, 2014 vest in equal annual installments over three years from the date of grant.  

The following table summarizes the activity of the Company’s Restricted Stock Units:

 

 

Number of
RSUs

 

 

Weighted-
Average
Grant
Date
Fair Value

 

Unvested at September 30, 2013

 

 

 

$

 

Granted

 

510,000

 

 

 

14.58

 

Vested

 

 

 

 

 

Forfeited

 

 

 

 

 

Unvested at September 30, 2014

 

510,000

  

 

$

14.58

 

Granted

 

30,000

 

 

 

5.22

 

Vested

 

 

 

 

 

Forfeited

 

 

 

 

 

Unvested at December 31, 2014

 

540,000

 

 

$

14.06

 

The Company recorded $1,033,457 and $0 of expense relating to restricted stock units during the three months ended December 31, 2014 and 2013, respectively, and such expense is included in stock-based compensation expense in the Company’s Consolidated Statement of Operations.  

As of December 31, 2014, the pre-tax compensation expense for all unvested restricted stock units in the amount of approximately $4,036,658 will be recognized in the Company’s results of operations over a weighted average period of 1.4 years.

12


 

NOTE 8. FAIR VALUE MEASUREMENTS

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows:

Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly.

Level 3—Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date.

The following table summarizes fair value measurements at December 31, 201 4 and September 30, 2014 for assets and liabilities measured at fair value on a recurring basis:

December 31, 201 4 :

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash and cash equivalents

$

103,991,231

 

 

$

 

 

$

 

 

$

103,991,231

 

Derivative liabilities

$

 

 

$

 

 

$

1,790,559

 

 

$

1,790,559

 

Acquisition-related contingent consideration obligations

$

 

 

$

 

 

$

3,970,931

 

 

$

3,970,931

 

September 30, 2014 :

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash and cash equivalents

$

132,510,610

 

 

$

 

 

$

 

 

$

132,510,610

 

Derivative liabilities

$

 

 

$

 

 

$

4,173,943

 

 

$

4,173,943

 

Acquisition-related contingent consideration obligations

$

 

 

$

 

 

$

3,970,931

 

 

$

3,970,931

 

The Company invests its excess cash balances in short and long-term corporate bonds, generally with remaining maturities of less than two years.  At December 31, 2014, the Company had short-term investments of $23,532,402, and long-term investments of $17,806,499, for a total of $41,338,901.  The fair value of its investment at December 31, 2014 was $40,759,068.  The Company expects to hold such investments until maturity, and thus unrealized gains and losses from the fluctuations in the fair value of the securities are not likely to be realized.

As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the “2010 Warrants”), of which 24,324 warrants were outstanding at December 31, 2014. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the “2012 Warrants”) of which 265,161 warrants were outstanding at December 31, 2014.  Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the “2013 Warrants”) of which 12,123 warrants were outstanding at December 31, 2014 (collectively the “Warrants”).  Each of the Warrants discussed above contains a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the terms of the Warrants, the Company issues Common Stock at a price lower than the exercise price for the Warrants, the exercise price would be reduced to the amount equal to the issuance price of the Common Stock.  As a result of these features, the Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company’s Consolidated Balance Sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a non-operating gain or loss as change in value of derivatives in the Company’s Consolidated Statement of Operations. During the three months ended December 31, 2014, the Company recorded a non-cash gain from the change in fair value of the derivative liability of $2,179,651, and during the three months ended December 31, 2013, the Company recorded a non-cash loss of $3,507,496.

13


The assumptions used in valuing the derivative liability were as follows:

 

2010 Warrants

 

December 31, 2014

 

 

September 30, 2014

Risk free interest rate

 

0.25%

 

 

0.13%

Expected life

 

1.0 Years

 

 

1.2 Years

Dividend yield

 

None

 

 

None

Volatility

 

75%

 

 

69%

 

 

 

 

 

 

2012 Warrants

 

December 31, 2014

 

 

September 30, 2014

Risk free interest rate

 

1.10%

 

 

1.07%

Expected life

 

3.0 Years

 

 

3.2 Years

Dividend yield

 

None

 

 

None

Volatility

 

75%

 

 

69%

 

 

 

 

 

 

2013 Warrants

 

December 31, 2014

 

 

September 30, 2014

Risk free interest rate

 

1.10%

 

 

1.07%

Expected life

 

3.1 Years

 

 

3.3 Years

Dividend yield

 

None

 

 

None

Volatility

 

75%

 

 

69%

The following is a reconciliation of the derivative liability related to these warrants:

 

Value at September 30, 2013

$

4,091,797

 

Issuance of instruments

 

 

Change in value

 

5,821,796

 

Net settlements

 

(5,956,079

)

Value at September 30, 2014

$

3,957,514

 

Issuance of instruments

 

 

Change in value

 

(2,179,651)

 

Net settlements

 

 

Value at December 31, 201 4

$

1,777,863

 

 

 

 

 

In conjunction with the financing of Ablaris in fiscal 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares of Common Stock based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares. This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold in fiscal 2011, and 585,000 remain outstanding at December 31, 2014. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company’s Consolidated Balance Sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a non-operating gain or loss in the Company’s Consolidated Statement of Operations. During the three months ended December 31, 201 4 , the Company recorded a non-cash gain from the change in fair value of the derivative liability of $202,491 and during the three months ended December 31, 2013, the Company recorded a non-cash loss of $12,082.

The assumptions used in valuing the derivative liability were as follows:

 

 

December  31,  201 4

 

September 30,  2014

Risk free interest rate

1.27%

 

1.07%

Expected life

3.0 Years

 

3.3 Years

Dividend yield

None